NCT02415153 - Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 14, 2015

Primary Completion Date

July 1, 2019

Study Completion Date

May 27, 2020

Conditions

Neurofibromatosis Type 1Recurrent Childhood Brain Stem GliomaRecurrent Childhood Visual Pathway GliomaRecurrent Primary Central Nervous System NeoplasmRefractory Primary Central Nervous System Neoplasm

Interventions

OTHER

Laboratory Biomarker Analysis

Optional correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Pomalidomide

Given PO

Trial Locations (12)

10065

Memorial Sloan Kettering Cancer Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

20850

National Cancer Institute, Rockville

20892

National Institutes of Health Clinical Center, Bethesda

27710

Duke University Medical Center, Durham

38105

Saint Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60611

Lurie Children's Hospital-Chicago, Chicago

77030

Texas Children's Hospital, Houston

90027

Children's Hospital Los Angeles, Los Angeles

94304

Lucile Packard Children's Hospital Stanford University, Palo Alto

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH